Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Cubist Pharmaceuticals, Inc. (CBST) Reports In-Line Q4 EPS
January 23, 2013 4:01 PM ESTCubist Pharmaceuticals, Inc. (NASDAQ: CBST) reported Q4 EPS of $0.48, in-line with the analyst estimate of $0.48. Revenue for the quarter came in at $245.9 million versus the consensus estimate of $246.42 million.
For earnings history and earnings-related data on Cubist Pharmaceuticals, Inc. (CBST) click here.... More
